During the coming five years, Truly Labs will play a significant role in the European project TRISTAN, in collaboration with experts at 20 companies and universities. The objective is to develop imaging tools for safety assessment of new drugs and drugs in development, specifically for lung and liver toxicity and bio-distribution of biologics.
Truly Labs is one of three SMEs that eventually will provide commercial services based on the products, qualified imaging biomarkers. This will ensure sustainability of the developed biomarkers. Also, it will offer pharmaceutical and biotech companies access to valuable safety assessment imaging tools.
– We are happy that Truly Labs and the project received funding, which gives Truly Labs great opportunities. Also, it is a recognition of their competences. Being a SmiLe company, they have access to SmiLe´s well-equipped laboratories and analysis intruments, as well as our community of life science companies and experts, says Ebba Fåhraeus, CEO of Smile Incubator.
For further information regarding TRISTAN, please see the TRISTAN press release
Truly Labs is a company at the SmiLe Incubator in the life science cluster in Lund, Sweden
For information regarding Truly Labs and TRISTAN, please contact:
Karin von Wachenfeldt, CEO, Truly Labs AB, email: Karin@trulylabs.com, phone: +46 723 111 589
About Truly Labs: Truly Labs is a preclinical CRO that provides tailor-made in vitro and in vivo services. Study design, performance, data evaluation and reporting – with extensive knowledge and experience in drug development we can support the progression of your projects.